Daraxonrasib Cuts Death Risk 60% in Phase 3 Pancreatic Cancer Trial - The Clinical Trial Vanguard

1. Daraxonrasib Cuts Death Risk 60% in Phase 3 Pancreatic Cancer Trial  The Clinical Trial Vanguard
2. Daily pill doubles survival time for pancreatic cancer patients  BBC
3. Daily pill can double survival time for world’s deadliest cancer, trial shows  The Guardian
4. ‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long  The Washington Post
5. Revolution's pancreatic cancer drug doubles survival, boosts quality of life  ETPharma.com

source https://news.google.com/rss/articles/CBMirwFBVV95cUxQMFVTRG9vXzV4YkVNNXhpSFNFaFhCUlAyNUpfdzhSQlUxR05QVlZrVHNfTWUzaWtUcUhRWnN4eXc1aGZIQ0Iwd09pdG0zYzFVZGM5ODQzUEE0cEZKSjctT0NWZkRyU1Z4QjY4OGhoekhrblhGQ055MDlPN19HWXdYWi1jQnFuMFZjUDU4V1JaOTJPbTBKS3plWG5mbGJ3YXB5blgyOHJUTTVpekF6OGRr?oc=5